SCHEMBL6252674

SCHEMBL6252674

O=C(OC[C@H]1O[C@H](OC(=O)c2ccccc2)[C@H](OC(=O)c2ccccc2)[C@H]1OC(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 4/20 0.68
PTPN2 P17706 1/20 0.60
PTPN11 Q06124 1/20 0.60
F11 P03951 2/20 0.58
USP2 O75604 2/20 0.58
CA1 P00915 2/20 0.58
CA2 P00918 2/20 0.58
MAPK1 P28482 2/20 0.58
TMPRSS2 O15393 1/20 0.58
PDE5A O76074 1/20 0.58
HMGCR P04035 1/20 0.58
CYP1A2 P05177 1/20 0.58
LCK P06239 1/20 0.58
FYN P06241 1/20 0.58
HSPD1 P10809 1/20 0.58
CYP2C9 P11712 1/20 0.58
CA6 P23280 1/20 0.58
TBXAS1 P24557 1/20 0.58
MAPK3 P27361 1/20 0.58
HSPE1 P61604 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15814640 1.00 PTPN1 (0.68) PTPN1PTPN2PTPN11F11USP2
SCHEMBL14356268 1.00 PTPN1 (0.68) PTPN1PTPN2PTPN11F11USP2
SCHEMBL17326916 1.00 PTPN1 (0.68) PTPN1PTPN2PTPN11F11USP2
SCHEMBL14037294 1.00 PTPN1 (0.68) PTPN1PTPN2PTPN11F11USP2
SCHEMBL4875707 1.00 PTPN1 (0.68) PTPN1PTPN2PTPN11F11USP2
SCHEMBL14011212 1.00 PTPN1 (0.68) PTPN1PTPN2PTPN11F11USP2
SCHEMBL6252668 1.00 PTPN1 (0.68) PTPN1PTPN2PTPN11F11USP2
SCHEMBL12154605 1.00 PTPN1 (0.68) PTPN1PTPN2PTPN11F11USP2
SCHEMBL19090430 1.00 PTPN1 (0.68) PTPN1PTPN2PTPN11F11USP2
SCHEMBL15814641 1.00 PTPN1 (0.68) PTPN1PTPN2PTPN11F11USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1572709-A3 USE OF NUCLEOSIDE COMPOUNDS FOR NONSENSE SUPPRESSION AND THE TREATMENT OF GENETIC DISEASES PTC Therapeutics, Inc. (US) 2005-11-23 EP disclosed
EP-1572709-A2 USE OF NUCLEOSIDE COMPOUNDS FOR NONSENSE SUPPRESSION AND THE TREATMENT OF GENETIC DISEASES PTC Therapeutics, Inc. (US) 2005-09-14 EP disclosed
WO-2004009610-A2 USE OF NUCLEOSIDE COMPOUNDS FOR NONSENSE SUPPRESSION AND THE TREATMENT OF GENETIC DISEASES PTC THERAPEUTICS, INC. (US) 2004-01-29 WO disclosed